We herewith submit unaudited financial result for the quarter and Nine months ended on 31st December, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Link Pharma Chem's Board approved Q3 FY26 (ended Dec 2025) and nine-month unaudited results. Revenue from operations rose to Rs 673.47 lakhs in Q3, up about 26% from Rs 534.24 lakhs in the same quarter last year. For the nine months, revenue grew to Rs 2,084.27 lakhs from Rs 1,898.68 lakhs (about 10% YoY). The company swung back to profit, posting a Q3 PAT of Rs 6.82 lakhs versus a loss of Rs 66.71 lakhs a year ago, while nine-month PAT stood at Rs 28.55 lakhs compared to a loss of Rs 67.71 lakhs. Total expenses rose only modestly, supporting the margin improvement. The statutory auditor (CNK & Associates LLP) issued a clean limited review report with no qualifications. The company also noted that new Indian Labour Codes effective November 21, 2025 have no material financial impact on its results.
A return to profitability after consecutive losses, combined with double-digit quarterly revenue growth, is a positive signal for shareholders. The clean auditor review and absence of material concerns from new Labour Codes reinforce the turnaround narrative.